Alpha Tau Medical stock reports a USD 45.8 million Q2 loss

Alpha Tau Medical stock is framed by a USD 45.8 million net loss for Q2 2026, reported on August 10, 2026, while the oncology company advances several late-stage clinical programs. The financial result makes cash discipline and trial execution the two figures that matter most for the investment case.

Quarterly loss widens the test

According to MarketBeat, Alpha Tau reported quarterly earnings per share of minus USD 0.50, versus a consensus loss of USD 0.14. The USD 0.36 per-share miss shows why clinical progress must be weighed against financing and warrant-related costs.

The six-month picture was also demanding. Quartr reported a net loss of USD 68.8 million for the six months ended June 30, 2026, compared with USD 18.8 million in the prior-year period. Cash and equivalents reached USD 104.8 million on June 30, 2026, up from USD 76.9 million at the end of 2025.

Trial enrollment supplies a counterweight

Alpha Tau completed enrollment of 48 patients in the IMPACT pilot study for pancreatic adenocarcinoma. The study combines intratumoral Alpha DaRT with first-line chemotherapy, and the company expects topline data in early 2027, according to Investing.com.

The analyst response was constructive but measured. H.C. Wainwright maintained a Buy rating and raised its price target from USD 15.00 to USD 16.00 on September 1, 2026, after enrollment was completed. The new target is 6.38 percent above the USD 15.04 primary-market quote dated September 28, 2026, although that dollar quotation is separate from the euro reference price required for German investors.

Market value and range

On September 28, 2026, Alpha Tau Medical had a market capitalization of USD 1.4 billion and a 52-week range of USD 3.43 to USD 15.79. The stock therefore sits near the top of its annual range, while the quarterly loss keeps clinical milestones central to the valuation debate.